By Albert Hecht On Monday, September 11th, 2017

New Teva CEO Kare Schultz Grants $20 Million in Cash, $13.5 Million in Securities

New Teva CEO Kare Schultz will earn an annual salary of $2 million and a performance-dependent bonus of 140% of the base salary – and up to a maximum of 200%. The Israeli Teva Pharmaceutical Industries has More...

By Jewish Business News On Monday, September 11th, 2017

Israeli Troubled Teva Appoints Kare Schultz CEO

  Teva‘s share price is up by more than 8% on the Tel Aviv Stock Exchange after the Israeli pharmaceutical company Named its new Kare Schultz as President and Chief Executive Officer. Kare Schultz, More...

By Jewish Business News On Thursday, August 31st, 2017

Dual-Listed BiondVax to Voluntarily Delist From Tel Aviv Stock Exchange

BiondVax Pharmaceuticals Ltd., developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while More...

By Alan Gallindoss On Monday, August 28th, 2017

A Huge Exit on Israeli Biomed: Gilead Buys Kite Pharma for $11.9 Billion in Cash

  Gilead Sciences agreed on Monday to buy Kite Pharma for $11.9 billion in an all-cash deal. This acquisition is one of the biggest ever of a company whose products have not yet approved for marketing. Gilead More...

By Jewish Business News On Sunday, August 20th, 2017

Teva Launches Generic Testosterone Boost Treatment

Teva Pharmaceutical Industries Ltd. today announced the launch of generic Axiron (testosterone) topical solution CIII, 30 mg/1.5 mL, in the US. Testosterone topical solution CIII is a prescription medicine used More...

By Nir Eyal On Sunday, August 6th, 2017

Teva Crashes 18% on Tel Aviv Trading Opens, Loses Third of Its Value in Two Days

  Teva Pharmaceutical Industries Ltd. opened Sunday morning with another hit. The Israeli giant plummeted 17.6% down on the Tel Aviv Stock Exchange after losing 17.79% on Thursday. The company announced on More...

By Omri Cohen On Thursday, August 3rd, 2017

Drama in Teva: Cutting 7,000 Jobs in 45 Countries ; Share Price Plunges

Teva Pharmaceutical Industries announced today that it is cutting 7,000 jobs in 45 countries and will close 15 factories by the end of 2018, following the publication of the financial results of the company for More...

By Jewish Business News On Monday, July 24th, 2017

Israeli Biomed NeuroDerm Sells for $1.1 Billion in Cash to Japanese Mitsubishi Tanabe

In the largest biomed acquisition in Israel, and one of the largest deals in the Israeli economy in general, biomed NeuroDerm is sold for $ 1.1 billion in cash to Japanese Mitsubishi Tanabe Pharma. NeuroDerm is More...

By Jewish Business News On Sunday, May 7th, 2017

Teva and Active Biotech Announce CONCERTO Trial of Laquinimod Trial Fails

   Teva Pharmaceutical Industries Ltd. and its partner Active Biotech reported on Friday that the CONCERTO trial of its ethical drug laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) More...

By Jewish Business News On Thursday, March 30th, 2017

Israeli BiondVax to Build Facility for Commercial Production of Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd. today announced that the Israel Investment Center, a unit of the Government of Israel’s Ministry of Economy and Industry, approved a grant representing 20 percent of a NIS 20 million More...


Delivered by FeedBurner